ICON PLC
ICLRIcon plc (stylized as "ICON") is an Irish-headquartered multinational clinical research organisation (CRO). Icon conducts clinical trials on behalf of pharmaceutical and biotechnology companies and provides services related to drug development and guiding clinical trial progress.
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Dexamethasone | Phase 3 | Cataract | - | - |
IBI-10090 | Phase 3 | Inflammation | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ICON PLC's drug pipeline?→
CatalystAlert tracks 2 drug candidates in ICON PLC's (ICLR) pipeline across Phase 3. Its lead program is Dexamethasone (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ICON PLC's next FDA catalyst?→
ICON PLC's (ICLR) next tracked catalyst is a Earnings expected July 29, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ICLR biotech catalysts?→
Add ICLR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ICON PLC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.